The cAMP pathway as therapeutic target in autoimmune and inflammatory diseases

Frontiers in Immunology

Volumn 7, Issue MAR, 2016, Pages

  Raker, Verena Katharina ^a   Becker, Christian ^a   Steinbrink, Kerstin ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Autoimmunity; Cyclic AMP; Inflammation; T cells; T regulatory cells; Targeted therapies; Tregs

Indexed keywords

CYCLIC AMP; CYCLIC NUCLEOTIDE GATED CHANNEL; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE EXCHANGE FACTOR;

ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; CELL FUNCTION; CYCLIC AMP RESPONSIVE ELEMENT; DENDRITIC CELL; GRANULOCYTE; HOMEOSTASIS; HUMAN; INFLAMMATORY DISEASE; MONOCYTE; NATURAL KILLER CELL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

EID: 84964587768     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00123     Document Type: Review

References (155)

1. Taskén K, Skålhegg BS, Taskén KA, Solberg R, Knutsen HK, Levy FO, et al. Structure, function, and regulation of human cAMP-dependent protein kinases. Adv Second Messenger Phosphoprotein Res (1997) 31:191-204. doi: 10.1016/S1040-7952(97)80019-5.
2. Sutherland EW, Rall TW. Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles. J Biol Chem (1958) 232:1077-91.
3. Beavo JA, Brunton LL. Cyclic nucleotide research - still expanding after half a century. Nat Rev Mol Cell Biol (2002) 3:710-8. doi:10.1038/nrm911.
4. Dessauer CW. Adenylyl cyclase - A-kinase anchoring protein complexes: the next dimension in cAMP signaling. Mol Pharmacol (2009) 76:935-41. doi:10.1124/mol.109.059345.
5. Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem (2007) 76:481-511. doi:10.1146/annurev.biochem.76.060305.150444.
6. Erdogan S, Houslay MD. Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant. Biochem J (1997) 321(Pt 1):165-75.
7. Loriaux MM, Rehfuss RP, Brennan RG, Goodman RH. Engineered leucine zippers show that hemiphosphorylated CREB complexes are transcriptionally active. Proc Natl Acad Sci U S A (1993) 90:9046-50. doi:10.1073/pnas.90.19.9046.
8. Page CP, Spina D. Phosphodiesterase inhibitors in the treatment of inflammatory diseases. Handb Exp Pharmacol (2011) 204:391-414. doi:10.1007/978-3-642-17969-3_17.
9. Cote RH. Characteristics of photoreceptor PDE (PDE6): similarities and differences to PDE5. Int J Impot Res (2004) 16(Suppl 1):S28-33. doi:10.1038/sj.ijir.3901212.
10. Begum N, Shen W, Manganiello V. Role of PDE3A in regulation of cell cycle progression in mouse vascular smooth muscle cells and oocytes: implications in cardiovascular diseases and infertility. Curr Opin Pharmacol (2011) 11:725-9. doi:10.1016/j.coph.2011.10.006.
11. Wang Z-Z, Zhang Y, Zhang H-T, Li Y-F. Phosphodiesterase: an interface connecting cognitive deficits to neuropsychiatric and neurodegenerative diseases. Curr Pharm Des (2015) 21:303-16. doi:10.2174/1381612820666140826115559.
12. Walsh DA, Perkins JP, Krebs EG. An adenosine -3',5'-monophosphate-dependant protein kinase from rabbit skeletal muscle. J Biol Chem (1968) 243:3763-5.
13. Shabb JB. Physiological substrates of cAMP-dependent protein kinase. Chem Rev (2001) 101:2381-411. doi:10.1021/cr000236l.
14. Sassone-Corsi P. Transcription factors responsive to cAMP. Annu Rev Cell Dev Biol (1995) 11:355-77. doi:10.1146/annurev.cb.11.110195.002035.
15. Mayr B, Montminy M. Transcriptional regulation by the -phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol (2001) 2:599-609. doi:10.1038/35085068.
16. Matulef K, Zagotta WN. Cyclic nucleotide-gated ion channels. Annu Rev Cell Dev Biol (2003) 19:23-44. doi:10.1146/annurev.cellbio.19.110701.154854.
17. de Rooij J, Zwartkruis FJ, Verheijen MH, Cool RH, Nijman SM, Wittinghofer A, et al. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature (1998) 396:474-7. doi:10.1038/24884.
18. Kawasaki H, Springett GM, Mochizuki N, Toki S, Nakaya M, Matsuda M, et al. A family of cAMP-binding proteins that directly activate Rap1. Science (1998) 282:2275-9. doi:10.1126/science.282.5397.2275.
19. Dao KK, Teigen K, Kopperud R, Hodneland E, Schwede F, Christensen AE, et al. Epac1 and cAMP-dependent protein kinase holoenzyme have similar cAMP affinity, but their cAMP domains have distinct structural features and cyclic nucleotide recognition. J Biol Chem (2006) 281:21500-11. doi:10.1074/jbc. M603116200.
20. Edwards AS, Scott JD. A-kinase anchoring proteins: protein kinase A and beyond. Curr Opin Cell Biol (2000) 12:217-21. doi:10.1016/S0955-0674(99)00085-X.
21. Filadi R, Pozzan T. Generation and functions of second messengers microdomains. Cell Calcium (2015) 58:405-14. doi:10.1016/j.ceca.2015.03.007.
22. AronoffDM, Canetti C, Serezani CH, Luo M, Peters-Golden M. Cutting edge: macrophage inhibition by cyclic AMP (cAMP): differential roles of protein kinase A and exchange protein directly activated by cAMP-1. J Immunol (2005) 174:595-9. doi:10.4049/jimmunol.174.2.595.
23. Pierre S, Eschenhagen T, Geisslinger G, Scholich K. Capturing adenylyl cyclases as potential drug targets. Nat Rev Drug Discov (2009) 8:321-35. doi:10.1038/nrd2827.
24. Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC. Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov (2014) 13:290-314. doi:10.1038/nrd4228.
25. Houslay MD, Baillie GS, Maurice DH. cAMP-specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling. Circ Res (2007) 100:950-66. doi:10.1161/01.RES.0000261934.56938.38.
26. Kritzer MD, Li J, Dodge-Kafka K, KapiloffMS. AKAPs: the architectural underpinnings of local cAMP signaling. J Mol Cell Cardiol (2012) 52:351-8. doi:10.1016/j.yjmcc.2011.05.002.
27. Kumar NM, Gilula NB. The gap junction communication channel. Cell (1996) 84:381-8. doi:10.1016/S0092-8674(00)81282-9.
28. Gödecke A. cAMP: fuel for extracellular adenosine formation? Br J Pharmacol (2008) 153:1087-9. doi:10.1038/bjp.2008.7.
29. Enjyoji K, Sévigny J, Lin Y, Frenette PS, Christie PD, Esch JS, et al. Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med (1999) 5:1010-7. doi:10.1038/12447.
30. Koszalka P, Ozüyaman B, Huo Y, Zernecke A, Flögel U, Braun N, et al. Targeted disruption of cd73/ecto-5'-nucleotidase alters thromboregulation and augments vascular inflammatory response. Circ Res (2004) 95:814-21. doi:10.1161/01.RES.0000144796.82787.6f.
31. Kurtz CC, Alam MS, Ernst PB. Extracellular adenosine production is essential for Treg-mediated Th cell suppression. FASEB J (2008) 22:848.26. doi:10.1096/fj.1530-6860.
32. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med (2007) 204:1257-65. doi:10.1084/jem.20062512.
33. Sciaraffia E, Riccomi A, Lindstedt R, Gesa V, Cirelli E, Patrizio M, et al. Human monocytes respond to extracellular cAMP through A2A and A2B adenosine receptors. J Leukoc Biol (2014) 96:113-22. doi:10.1189/jlb.3A0513-302RR.
34. Serezani CH, Ballinger MN, AronoffDM, Peters-Golden M. Cyclic AMP: master regulator of innate immune cell function. Am J Respir Cell Mol Biol (2008) 39:127-32. doi:10.1165/rcmb.2008-0091TR.
35. Xu XJ, Reichner JS, Mastrofrancesco B, Henry WL, Albina JE. Prostaglandin E2 suppresses lipopolysaccharide-stimulated IFN-beta production. J Immunol (2008) 180:2125-31. doi:10.4049/jimmunol.180.4.2125.
36. Papac-Milicevic N, Breuss JM, Zaujec J, Ryban L, Plyushch T, Wagner GA, et al. The interferon stimulated gene 12 inactivates vasculoprotective functions of NR4A nuclear receptors. Circ Res (2012) 110:e50-63. doi:10.1161/CIRCRESAHA.111.258814.
37. Jutila MA, Kroese FG, Jutila KL, Stall AM, Fiering S, Herzenberg LA, et al. Ly-6C is a monocyte/macrophage and endothelial cell differentiation antigen regulated by interferon-gamma. Eur J Immunol (1988) 18(11):1819-26. doi:10.1002/eji.1830181125.
38. Hanna RN, Carlin LM, Hubbeling HG, Nackiewicz D, Green AM, Punt JA, et al. The transcription factor NR4A1 (Nur77) controls bone marrow differentiation and the survival of Ly6C- monocytes. Nat Immunol (2011) 12:778-85. doi:10.1038/ni.2063.
39. Carry J-C, Clerc F, Minoux H, Schio L, Mauger J, Nair A, et al. SAR156497, an exquisitely selective inhibitor of aurora kinases. J Med Chem (2015) 58:362-75. doi:10.1021/jm501326k.
40. Pei L, Castrillo A, Chen M, Hoffmann A, Tontonoz P. Induction of NR4A orphan nuclear receptor expression in macrophages in response to inflammatory stimuli. J Biol Chem (2005) 280:29256-62. doi:10.1074/jbc. M502606200.
41. Maxwell MA, Muscat GEO. The NR4A subgroup: immediate early response genes with pleiotropic physiological roles. Nucl Recept Signal (2006) 4:e002. doi:10.1621/nrs.04002.
42. Bystrom J, Evans I, Newson J, Stables M, Toor I, van Rooijen N, et al. Resolution-phase macrophages possess a unique inflammatory phenotype that is controlled by cAMP. Blood (2008) 112:4117-27. doi:10.1182/blood-2007-12-129767.
43. Nokta MA, Pollard RB. Human immunodeficiency virus replication: modulation by cellular levels of cAMP. AIDS Res Hum Retroviruses (1992) 8:1255-61. doi:10.1089/aid.1992.8.1255.
44. Fülöp T, Fóris G, Wórum I, Leövey A. Age-dependent alterations of Fc gamma receptor-mediated effector functions of human polymorphonuclear leucocytes. Clin Exp Immunol (1985) 61:425-32.
45. Wirth JJ, Kierszenbaum F. Macrophage mediation of the inhibitory effects of elevated intracellular levels of adenosine-3':5' cyclic monophosphate (cAMP) on macrophage-Trypanosoma cruzi association. Int J Parasitol (1984) 14:401-4. doi:10.1016/0020-7519(84)90096-1.
46. Tian J, Rui K, Tang X, Ma J, Wang Y, Tian X, et al. MicroRNA-9 regulates the differentiation and function of myeloid-derived suppressor cells via targeting Runx1. J Immunol (2015) 195:1301-11. doi:10.4049/jimmunol.1500209.
47. Dent G, Giembycz MA, Rabe KF, Wolf B, Barnes PJ, Magnussen H. Theophylline suppresses human alveolar macrophage respiratory burst through phosphodiesterase inhibition. Am J Respir Cell Mol Biol (1994) 10:565-72. doi:10.1165/ajrcmb.10.5.8179921.
48. Rowe J, Finlay-Jones JJ, Nicholas TE, Bowden J, Morton S, Hart PH. Inability of histamine to regulate TNF-alpha production by human alveolar macrophages. Am J Respir Cell Mol Biol (1997) 17:218-26. doi:10.1165/ajrcmb.17.2.2722.
49. Abrahamsen H, Baillie G, Ngai J, Vang T, Nika K, Ruppelt A, et al. TCR- and CD28-mediated recruitment of phosphodiesterase 4 to lipid rafts potentiates TCR signaling. J Immunol (2004) 173:4847-58. doi:10.4049/jimmunol.173.8.4847.
50. Wall EA, Zavzavadjian JR, Chang MS, Randhawa B, Zhu X, Hsueh RC, et al. Suppression of LPS-induced TNF-α production in macrophages by cAMP is mediated by PKA-AKAP95-p105. Sci Signal (2009) 2:ra28-28. doi:10.1126/scisignal.2000202.
51. Baker DA, Kelly JM. Structure, function and evolution of microbial adenylyl and guanylyl cyclases. Mol Microbiol (2004) 52:1229-42. doi:10.1111/j.1365-2958.2004.04067.x.
52. Pezard C, Weber M, Sirard JC, Berche P, Mock M. Protective immunity induced by Bacillus anthracis toxin-deficient strains. Infect Immun (1995) 63:1369-72.
53. Coote JG. Structural and functional relationships among the RTX toxin determinants of Gram-negative bacteria. FEMS Microbiol Rev (1992) 8:137-61. doi:10.1111/j.1574-6968.1992.tb04961.x.
54. Agarwal N, Lamichhane G, Gupta R, Nolan S, Bishai WR. Cyclic AMP intoxication of macrophages by a Mycobacterium tuberculosis adenylate cyclase. Nature (2009) 460:98-102. doi:10.1038/nature08123.
55. Eby JC, Gray MC, Hewlett EL. Cyclic AMP-mediated suppression of neutrophil extracellular trap formation and apoptosis by the Bordetella pertussis adenylate cyclase toxin. Infect Immun (2014) 82:5256-69. doi:10.1128/IAI.02487-14.
56. Whalen MM, Bankhurst AD. Effects of beta-adrenergic receptor activation, cholera toxin and forskolin on human natural killer cell function. Biochem J (1990) 272:327-31. doi:10.1042/bj2720327.
57. Bariagaber AK, Whalen MM. Decreased adenylyl cyclase and -cAMP-dependent protein kinase activities inhibit the cytotoxic function of human natural killer cells. Hum Immunol (2003) 64:866-73. doi:10.1016/S0198-8859(03)00154-X.
58. Zhao W, Huang Y, Liu Z, Cao B-B, Peng Y-P, Qiu Y-H. Dopamine receptors modulate cytotoxicity of natural killer cells via cAMP-PKA-CREB signaling pathway. PLoS One (2013) 8:e65860. doi:10.1371/journal.pone.0065860.
59. Goto M, Murakawa M, Kadoshima-Yamaoka K, Tanaka Y, Inoue H, Murafuji H, et al. Phosphodiesterase 7A inhibitor ASB16165 suppresses proliferation and cytokine production of NKT cells. Cell Immunol (2009) 258:147-51. doi:10.1016/j.cellimm.2009.04.005.
60. Torgersen KM, Vaage JT, Levy FO, Hansson V, Rolstad B, Taskén K. Selective activation of cAMP-dependent protein kinase type I inhibits rat natural killer cell cytotoxicity. J Biol Chem (1997) 272:5495-500. doi:10.1074/jbc.272.9.5495.
61. Bäumer W, Hoppmann J, Rundfeldt C, Kietzmann M. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets (2007) 6:17-26. doi:10.2174/187152807780077318.
62. Oger S, Méhats C, Dallot E, Cabrol D, Leroy M-J. Evidence for a role of phosphodiesterase 4 in lipopolysaccharide-stimulated prostaglandin E2 production and matrix metalloproteinase-9 activity in human amniochorionic membranes. J Immunol (2005) 174:8082-9. doi:10.4049/jimmunol.174.12.8082.
63. Lee J, Kim TH, Murray F, Li X, Choi SS, Broide DH, et al. Cyclic AMP concentrations in dendritic cells induce and regulate Th2 immunity and allergic asthma. Proc Natl Acad Sci U S A (2015) 112:1529-34. doi:10.1073/pnas.1417972112.
64. Schett G, Sloan VS, Stevens RM, Schafer P. Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases. Ther Adv Musculoskelet Dis (2010) 2:271-8. doi:10.1177/1759720X10381432.
65. Heystek HC, Thierry A-C, Soulard P, Moulon C. Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity. Int Immunol (2003) 15:827-35. doi:10.1093/intimm/dxg079.
66. Datta SK, Sabet M, Nguyen KPL, Valdez PA, Gonzalez-Navajas JM, Islam S, et al. Mucosal adjuvant activity of cholera toxin requires Th17 cells and protects against inhalation anthrax. Proc Natl Acad Sci U S A (2010) 107:10638-43. doi:10.1073/pnas.1002348107.
67. Legler DF, Krause P, Scandella E, Singer E, Groettrup M. Prostaglandin E2 is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptors. J Immunol (2006) 176:966-73. doi:10.4049/jimmunol.176.2.966.
68. Harizi H, Juzan M, Grosset C, Rashedi M, Gualde N. Dendritic cells issued in vitro from bone marrow produce PGE(2) that contributes to the immunomodulation induced by antigen-presenting cells. Cell Immunol (2001) 209:19-28. doi:10.1006/cimm.2001.1785.
69. Gilbert KM, Hoffmann MK. cAMP is an essential signal in the induction of antibody production by B cells but inhibits helper function of T cells. J Immunol (1985) 135:2084-9.
70. Levy FO, Rasmussen AM, Taskén K, Skålhegg BS, Huitfeldt HS, Funderud S, et al. Cyclic AMP-dependent protein kinase (cAK) in human B cells: co-localization of type I cAK (RI alpha 2 C2) with the antigen receptor during anti-immunoglobulin-induced B cell activation. Eur J Immunol (1996) 26:1290-6. doi:10.1002/eji.1830260617.
71. Taskén K, Stokka AJ. The molecular machinery for cAMP-dependent immunomodulation in T-cells. Biochem Soc Trans (2006) 34:476-9. doi:10.1042/BST0340476.
72. Wortis HH, Teutsch M, Higer M, Zheng J, Parker DC. B-cell activation by crosslinking of surface IgM or ligation of CD40 involves alternative signal pathways and results in different B-cell phenotypes. Proc Natl Acad Sci U S A (1995) 92:3348-52. doi:10.1073/pnas.92.8.3348.
73. Cekic C, Sag D, Day Y-J, Linden J. Extracellular adenosine regulates naive T cell development and peripheral maintenance. J Exp Med (2013) 210:2693-706. doi:10.1084/jem.20130249.
74. Vang T, Torgersen KM, Sundvold V, Saxena M, Levy FO, Skålhegg BS, et al. Activation of the COOH-terminal Src kinase (Csk) by cAMP-dependent protein kinase inhibits signaling through the T cell receptor. J Exp Med (2001) 193:497-507. doi:10.1084/jem.193.4.497.
75. Liopeta K, Boubali S, Virgilio L, Thyphronitis G, Mavrothalassitis G, Dimitracopoulos G, et al. cAMP regulates IL-10 production by normal human T lymphocytes at multiple levels: a potential role for MEF2. Mol Immunol (2009) 46:345-54. doi:10.1016/j.molimm.2008.10.025.
76. Hedrich CM, Crispin JC, Rauen T, Ioannidis C, Apostolidis SA, Lo MS, et al. cAMP response element modulator a controls IL2 and IL17A expression during CD4 lineage commitment and subset distribution in lupus. Proc Natl Acad Sci U S A (2012) 109:16606-11. doi:10.1073/pnas.1210129109.
77. Vig M, George A, Sen R, Durdik J, Rath S, Bal V. Commitment of activated T cells to secondary responsiveness is enhanced by signals mediated by cAMP-dependent protein kinase A-I. Mol Pharmacol (2002) 62:1471-81. doi:10.1124/mol.62.6.1471.
78. Cone RE, Cochrane R, Lingenheld EG, Clark RB. Elevation of intracellular cyclic AMP induces an anergic-like state in Th1 clones. Cell Immunol (1996) 173:246-51. doi:10.1006/cimm.1996.0274.
79. Powell JD, Lerner CG, Ewoldt GR, Schwartz RH. The -180 site of the IL-2 promoter is the target of CREB/CREM binding in T cell anergy. J Immunol (1999) 163:6631-9.
80. Appleman LJ, Tzachanis D, Grader-Beck T, van Puijenbroek AA, Boussiotis VA. Helper T cell anergy: from biochemistry to cancer pathophysiology and therapeutics. J Mol Med (Berl) (2001) 78:673-83. doi:10.1007/s001090000180.
81. Kadoshima-Yamaoka K, Murakawa M, Goto M, Tanaka Y, Inoue H, Murafuji H, et al. Effect of phosphodiesterase 7 inhibitor ASB16165 on development and function of cytotoxic T lymphocyte. Int Immunopharmacol (2009) 9:97-102. doi:10.1016/j.intimp.2008.10.005.
82. Bodor J, Spetz AL, Strominger JL, Habener JF. cAMP inducibility of transcriptional repressor ICER in developing and mature human T lymphocytes. Proc Natl Acad Sci U S A (1996) 93:3536-41. doi:10.1073/pnas.93.8.3536.
83. Bopp T, Becker C, Klein M, Klein-Hessling S, Palmetshofer A, Serfling E, et al. Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med (2007) 204:1303-10. doi:10.1084/jem.20062129.
84. Oberle N, Eberhardt N, Falk CS, Krammer PH, Suri-Payer E. Rapid suppression of cytokine transcription in human CD4+CD25 T cells by CD4+Foxp3+ regulatory T cells: independence of IL-2 consumption, TGF-beta, and various inhibitors of TCR signaling. J Immunol (2007) 179:3578-87. doi:10.4049/jimmunol.179.6.3578.
85. Bopp T, Dehzad N, Reuter S, Klein M, Ullrich N, Stassen M, et al. Inhibition of cAMP degradation improves regulatory T cell-mediated suppression. J Immunol (2009) 182:4017-24. doi:10.4049/jimmunol.0803310.
86. Becker C, Taube C, Bopp T, Becker C, Michel K, Kubach J, et al. Protection from graft-versus-host disease by HIV-1 envelope protein -gp120-mediated activation of human CD4+CD25+ regulatory T cells. Blood (2009) 114:1263-9. doi:10.1182/blood-2009-02-206730.
87. Huang B, Zhao J, Lei Z, Shen S, Li D, Shen G-X, et al. miR-142-3p restricts cAMP production in CD4+CD25-T cells and CD4+CD25+ TREG cells by targeting AC9 mRNA. EMBO Rep (2009) 10:180-5. doi:10.1038/embor.2008.224.
88. Bazhin AV, Kahnert S, Kimpfler S, Schadendorf D, Umansky V. Distinct metabolism of cyclic adenosine monophosphate in regulatory and helper CD4+ T cells. Mol Immunol (2010) 47:678-84. doi:10.1016/j.molimm.2009.10.032.
89. Fassbender M, Gerlitzki B, Ullrich N, Lupp C, Klein M, Radsak MP, et al. Cyclic adenosine monophosphate and IL-10 coordinately contribute to nTreg cell-mediated suppression of dendritic cell activation. Cell Immunol (2010) 265:91-6. doi:10.1016/j.cellimm.2010.07.007.
90. Vaeth M, Gogishvili T, Bopp T, Klein M, Berberich-Siebelt F, Gattenloehner S, et al. Regulatory T cells facilitate the nuclear accumulation of inducible cAMP early repressor (ICER) and suppress nuclear factor of activated T cell c1 (NFATc1). Proc Natl Acad Sci U S A (2011) 108:2480-5. doi:10.1073/pnas.1009463108.
91. Klein M, Vaeth M, Scheel T, Grabbe S, Baumgrass R, Berberich-Siebelt F, et al. Repression of cyclic adenosine monophosphate upregulation disarms and expands human regulatory T cells. J Immunol (2012) 188:1091-7. doi:10.4049/jimmunol.1102045.
92. Bacher N, Raker V, Hofmann C, Graulich E, Schwenk M, Baumgrass R, et al. Interferon-a suppresses cAMP to disarm human regulatory T cells. Cancer Res (2013) 73:5647-56. doi:10.1158/0008-5472.CAN-12-3788.
93. Martin H, Reuter S, Dehzad N, Heinz A, Bellinghausen I, Saloga J, et al. CD4-mediated regulatory T-cell activation inhibits the development of disease in a humanized mouse model of allergic airway disease. J Allergy Clin Immunol (2012) 129:e1-7. doi:10.1016/j.jaci.2011.09.038.
94. Lahl K, Mayer CT, Bopp T, Huehn J, Loddenkemper C, Eberl G, et al. Nonfunctional regulatory T cells and defective control of Th2 cytokine production in natural scurfy mutant mice. J Immunol (2009) 183:5662-72. doi:10.4049/jimmunol.0803762.
95. Vahl JC, Drees C, Heger K, Heink S, Fischer JC, Nedjic J, et al. Continuous T cell receptor signals maintain a functional regulatory T cell pool. Immunity (2014) 41:722-36. doi:10.1016/j.immuni.2014.10.012.
96. Gavin MA, Torgerson TR, Houston E, DeRoos P, Ho WY, Stray-Pedersen A, et al. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci U S A (2006) 103:6659-64. doi:10.1073/pnas.0509484103.
97. Becker C, Bopp T, Steinbrink K. Interferon a interferes with immunological tolerance. Oncoimmunology (2013) 2:e27528. doi:10.4161/onci.27528.
98. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol (2005) 5:375-86. doi:10.1038/nri1604.
99. Peter D, Jin SLC, Conti M, Hatzelmann A, Zitt C. Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: predominant role of PDE4D. J Immunol (2007) 178:4820-31. doi:10.4049/jimmunol.178.8.4820.
100. Chiricozzi A, Caposiena D, Garofalo V, Cannizzaro MV, Chimenti S, Saraceno R. A new therapeutic for the treatment of moderate to severe plaque psoriasis: apremilast. Expert Rev Clin Immunol (2015) 12:237-49. doi:10.1586/1744666X.2016.1134319.
101. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol (2010) 10:490-500. doi:10.1038/nri2785.
102. Kim H-P, Leonard WJ. CREB/ATF-dependent T cell receptor-induced FoxP3 gene expression: a role for DNA methylation. J Exp Med (2007) 204:1543-51. doi:10.1084/jem.20070109.
103. de la Rosa M, Rutz S, Dorninger H, Scheffold A. Interleukin-2 is essential for CD4+CD25+ regulatory T cell function. Eur J Immunol (2004) 34:2480-8. doi:10.1002/eji.200425274.
104. Barron L, Dooms H, Hoyer KK, Kuswanto W, Hofmann J, O'Gorman WE, et al. Cutting edge: mechanisms of IL-2-dependent maintenance of functional regulatory T cells. J Immunol (2010) 185:6426-30. doi:10.4049/jimmunol.0903940.
105. Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science (2006) 311:1924-7. doi:10.1126/science.1122927.
106. Webster KE, Walters S, Kohler RE, Mrkvan T, Boyman O, Surh CD, et al. In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J Exp Med (2009) 206:751-60. doi:10.1084/jem.20082824.
107. Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol (2015) 15:283-94. doi:10.1038/nri3823.
108. Kuczma M, Lee JR, Kraj P. Connexin 43 signaling enhances the generation of Foxp3+ regulatory T cells. J Immunol (2011) 187:248-57. doi:10.4049/jimmunol.1003785.
109. Rahmouni S, Aandahl EM, Nayjib B, Zeddou M, Giannini S, Verlaet M, et al. Cyclo-oxygenase type 2-dependent prostaglandin E2 secretion is involved in retrovirus-induced T-cell dysfunction in mice. Biochem J (2004) 384:469-76. doi:10.1042/BJ20031859.
110. Masci AM, Galgani M, Cassano S, De Simone S, Gallo A, De Rosa V, et al. HIV-1 gp120 induces anergy in naive T lymphocytes through CD4-independent protein kinase-A-mediated signaling. J Leukoc Biol (2003) 74:1117-24. doi:10.1189/jlb.0503239.
111. Moreno-Fernandez ME, Rueda CM, Rusie LK, Chougnet CA. Regulatory T cells control HIV replication in activated T cells through a cAMP-dependent mechanism. Blood (2011) 117:5372-80. doi:10.1182/blood-2010-12-323162.
112. Hofmann B, Nishanian P, Nguyen T, Liu M, Fahey JL. Restoration of T-cell function in HIV infection by reduction of intracellular cAMP levels with adenosine analogues. AIDS (1993) 7:659-64. doi:10.1097/00002030-199305000-00008.
113. Hofmann B, Nishanian P, Nguyen T, Insixiengmay P, Fahey JL. Human immunodeficiency virus proteins induce the inhibitory cAMP/protein kinase A pathway in normal lymphocytes. Proc Natl Acad Sci U S A (1993) 90:6676-80. doi:10.1073/pnas.90.14.6676.
114. Burzyn D, Kuswanto W, Kolodin D, Shadrach JL, Cerletti M, Jang Y, et al. A special population of regulatory T cells potentiates muscle repair. Cell (2013) 155:1282-95. doi:10.1016/j.cell.2013.10.054.
115. Braeuning A. The connection of β-catenin and phenobarbital in murine hepatocarcinogenesis: a critical discussion of Awuah et al., PLoS ONE 7(6):e39771, 2012. Arch Toxicol (2013) 87:401-2. doi:10.1007/s00204-012-1002-4.
116. Pavan B, Biondi C, Dalpiaz A. Adenylyl cyclases as innovative therapeutic goals. Drug Discov Today (2009) 14:982-91. doi:10.1016/j.drudis.2009.07.007.
117. Iwatsubo K, Minamisawa S, Tsunematsu T, Nakagome M, Toya Y, Tomlinson JE, et al. Direct inhibition of type 5 adenylyl cyclase prevents myocardial apoptosis without functional deterioration. J Biol Chem (2004) 279:40938-45. doi:10.1074/jbc. M314238200.
118. Okumura S, Kawabe J, Yatani A, Takagi G, Lee M-C, Hong C, et al. Type 5 adenylyl cyclase disruption alters not only sympathetic but also parasympathetic and calcium-mediated cardiac regulation. Circ Res (2003) 93:364-71. doi:10.1161/01.RES.0000086986.35568.63.
119. Alasbahi RH, Melzig MF. Plectranthus barbatus: a review of phytochemistry, ethnobotanical uses and pharmacology - part 2. Planta Med (2010) 76:753-65. doi:10.1055/s-0029-1240919.
120. Toya Y, Schwencke C, Ishikawa Y. Forskolin derivatives with increased selectivity for cardiac adenylyl cyclase. J Mol Cell Cardiol (1998) 30:97-108. doi:10.1006/jmcc.1997.0575.
121. Diamant Z, Spina D. PDE4-inhibitors: a novel, targeted therapy for obstructive airways disease. Pulm Pharmacol Ther (2011) 24:353-60. doi:10.1016/j.pupt.2010.12.011.
122. Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, Beume R, et al. The preclinical pharmacology of roflumilast - a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther (2010) 23:235-56. doi:10.1016/j.pupt.2010.03.011.
123. Zhang H-T. Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs. Curr Pharm Des (2009) 15:1688-98. doi:10.2174/138161209788168092.
124. Siuciak JA. The role of phosphodiesterases in schizophrenia: therapeutic implications. CNS Drugs (2008) 22:983-93. doi:10.2165/0023210-200822120-00002.
125. Millar JK, Pickard BS, Mackie S, James R, Christie S, Buchanan SR, et al. DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science (2005) 310:1187-91. doi:10.1126/science.1112915.
126. Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med (1998) 157:351-70. doi:10.1164/ajrccm.157.2.9708012.
127. Jin S-LC, Ding S-L, Lin S-C. Phosphodiesterase 4 and its inhibitors in inflammatory diseases. Chang Gung Med J (2012) 35:197-210.
128. Spina D, McFadzean I, Bertram FKR, Page CP. Peripheral mechanisms II: the pharmacology of peripherally active antitussive drugs. Handb Exp Pharmacol (2009) 187:155-86. doi:10.1007/978-3-540-79842-2_8.
129. Press NJ, Banner KH. PDE4 inhibitors - a review of the current field. Prog Med Chem (2009) 47:37-74. doi:10.1016/S0079-6468(08)00202-6.
130. Giembycz MA, Smith SJ. Phosphodiesterase 7A: a new therapeutic target for alleviating chronic inflammation? Curr Pharm Des (2006) 12:3207-20. doi:10.2174/138161206778194123.
131. Tenor H, Hatzelmann A, Kupferschmidt R, Stanciu L, Djukanovic R, Schudt C, et al. Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages. Clin Exp Allergy (1995) 25:625-33. doi:10.1111/j.1365-2222.1995.tb01110.x.
132. Tenor H, Staniciu L, Schudt C, Hatzelmann A, Wendel A, Djukanovic R, et al. Cyclic nucleotide phosphodiesterases from purified human CD4+ and CD8+ T lymphocytes. Clin Exp Allergy (1995) 25:616-24. doi:10.1111/j.1365-2222.1995.tb01109.x.
133. Robichaud A, Stamatiou PB, Jin S-LC, Lachance N, MacDonald D, Laliberté F, et al. Deletion of phosphodiesterase 4D in mice shortens -alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest (2002) 110:1045-52. doi:10.1172/JCI15506.
134. Naganuma K, Omura A, Maekawara N, Saitoh M, Ohkawa N, Kubota T, et al. Discovery of selective PDE4B inhibitors. Bioorg Med Chem Lett (2009) 19:3174-6. doi:10.1016/j.bmcl.2009.04.121.
135. Burgin AB, Magnusson OT, Singh J, Witte P, Staker BL, Bjornsson JM, et al. Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat Biotechnol (2010) 28:63-70. doi:10.1038/nbt.1598.
136. Page CP, Spina D. Selective PDE inhibitors as novel treatments for respiratory diseases. Curr Opin Pharmacol (2012) 12:275-86. doi:10.1016/j.coph.2012.02.016.
137. Kagayama K, Morimoto T, Nagata S, Katoh F, Zhang X, Inoue N, et al. Synthesis and biological evaluation of novel phthalazinone derivatives as topically active phosphodiesterase 4 inhibitors. Bioorg Med Chem (2009) 17:6959-70. doi:10.1016/j.bmc.2009.08.014.
138. Nazarian R, Weinberg JM. AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. Curr Opin Investig Drugs (2009) 10:1236-42.
139. Akama T, Baker SJ, Zhang Y-K, Hernandez V, Zhou H, Sanders V, et al. Discovery and structure-activity study of a novel benzoxaborole -anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. Bioorg Med Chem Lett (2009) 19:2129-32. doi:10.1016/j.bmcl.2009.03.007.
140. Conti M, Richter W, Mehats C, Livera G, Park J-Y, Jin C. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem (2003) 278:5493-6. doi:10.1074/jbc. R200029200.
141. Rennard SI, Calverley PMA, Goehring UM, Bredenbröker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD. Respir Res (2011) 12:18. doi:10.1186/1465-9921-12-18.
142. Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbröker D, Bethke TD. Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (2005) 366:563-71. doi:10.1016/S0140-6736(05)67100-0.
143. Calverley PMA, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri LM. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2007) 176:154-61. doi:10.1164/rccm.200610-1563OC.
144. Calverley PMA, Rabe KF, Goehring U-M, Kristiansen S, Fabbri LM, Martinez FJ. M2-124 and M2-125 study groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet (2009) 374:685-94. doi:10.1016/S0140-6736(09)61255-1.
145. Giembycz MA, Field SK. Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD. Drug Des Devel Ther (2010) 4:147-58.
146. Beghè B, Rabe KF, Fabbri LM. Phosphodiesterase-4 inhibitor therapy for lung diseases. Am J Respir Crit Care Med (2013) 188:271-8. doi:10.1164/rccm.201301-0021PP.
147. Mulhall AM, Droege CA, Ernst NE, Panos RJ, Zafar MA. Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs. Expert Opin Investig Drugs (2015) 24:1597-611. doi:10.1517/13543784.2015.1094054.
148. Man H-W, Schafer P, Wong LM, Patterson RT, Corral LG, Raymon H, et al. Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor. J Med Chem (2009) 52:1522-4. doi:10.1021/jm900210d.
149. Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, et al. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. J Rheumatol (2015) 42:479-88. doi:10.3899/jrheum.140647.
150. Zerilli T, Ocheretyaner E. Apremilast (Otezla): a new oral treatment for adults with psoriasis and psoriatic arthritis. P T (2015) 40:495-500.
151. Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RGB, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (efficacy and safety trial evaluating the effects of apremilast in psoriasis [ESTEEM] 1). J Am Acad Dermatol (2015) 73:37-49. doi:10.1016/j.jaad.2015.03.049.
152. Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis (2014) 73:1020-6. doi:10.1136/annrheumdis-2013-205056.
153. Delpiano MA, Acker H. Hypoxia increases the cyclic AMP content of the cat carotid body in vitro. J Neurochem (1991) 57:291-7. doi:10.1111/j.1471-4159.1991.tb02127.x.
154. Carmony KC, Kim K-B. PROTAC-induced proteolytic targeting. Methods Mol Biol (2012) 832:627-38. doi:10.1007/978-1-61779-474-2_44.
155. Zhang D, Baek SH, Ho A, Kim K. Degradation of target protein in living cells by small-molecule proteolysis inducer. Bioorg Med Chem Lett (2004) 14:645-8. doi:10.1016/j.bmcl.2003.11.042.